Search

for
Search:

Research

5 / 1000+ results

research A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results

138 citations , March 2021 in “Journal of the American Academy of Dermatology”

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

research A phase 2a trial of brepocitinib for cicatricial alopecia

17 citations , October 2024 in “Journal of the American Academy of Dermatology”

In this study, brepocitinib was found to significantly reduce inflammatory biomarker CCL5 expression and improve clinical severity by week 24, while maintaining a favorable safety profile.

research A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata

4 citations , July 2024 in “Pharmacology Research & Perspectives”

In this phase 2a study of adults with alopecia areata, researchers observed that ritlecitinib treatment did not result in significant differences in brainstem auditory evoked potential changes or axonal swelling compared to placebo, suggesting the dog toxicity findings may not be clinically relevant in humans.

research Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial

April 2026 in “medRxiv”

In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.

research Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial

20 citations , December 2021 in “Journal of the American Academy of Dermatology”

This study found that the oral JAK inhibitors ritlecitinib and brepocitinib were effective in maintaining hair regrowth in alopecia areata with continuous use, though efficacy decreased after withdrawal.

View more "phase 2a" in research →

Community Join

5 / 1000+ results

community Pp405 phase 2a clinical results

37 upvotes 1 year ago

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

community PP405 Phase 2a press release with early results

700 upvotes 1 year ago

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting

in Chat 30 upvotes 5 months ago

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

community Pelage PP405 Phase 2a completed.

61 upvotes 7 months ago

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

community Pelage to present PP405 Phase 2a clinical trial full results at an upcoming medical meeting - CMO Christina Weng says

748 upvotes 7 months ago

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

View more "phase 2a" in community →

Learn

3 / 801 results

learn Setipiprant

What is Setipiprant and how does it differ from DHT blockers like finasteride or dutasteride? Setipiprant blocks the prostaglandin D2 receptor DP2 rather than the DHT pathway that finasteride and dutasteride act on. The one published human trial — a 169-man, 24-week phase 2a study at 2,000 mg a day — reported no statistically significant improvement in hair density over placebo, and setipiprant is not an approved hair-loss medicine anywhere.

learn Overview

learn Finasteride

Finasteride Results Timeline: How Long It Takes to Work, Shedding Phases, and Expected Outcomes Trial data and community reports both put the first visible changes on finasteride at roughly 3 to 6 months, with the clearest results between 6 and 12 months; an early shedding phase is common and usually temporary. The benefit lasts only while the drug is taken, and it is prescription-only.

View more "phase 2a" in learn →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →